A Peak Year For Drug Approvals, But Can R&D Keep Up With FDA?
This article was originally published in RPM Report
FDA topped 40 new molecular entity approvals in 2014, leaving no doubt that the agency’s drug review group is operating at peak efficiency. But it is still far from clear that drug development is out of the doldrums.
You may also be interested in...
FDA continues to reshape the antibiotic regulatory pathway, both in word and in deed. The latest example of a collaborative, push-the-envelope review included a novel Actavis antibiotic formulation where FDA seemed ready to approve the drug without any human data. That was one step too far for the agency’s advisors.
FDA is still not ready to draw any clear line defining what qualifies for the new “Breakthrough” therapy designation, but most successful applicants have presented data showing more than a 50% improvement versus standard therapy on some important endpoint.
Gilead pays $125 million for the right to a faster review of a future product, doubling the price paid in the first priority review voucher sale just months before. The value of the voucher may go up if pending legislation is signed into law – but the high price tag speaks volumes about the importance of maintaining the lead in Hep C formulation development.